Isohype 300 Tablet contains Isoniazid 300 mg, a core drug used in the treatment and prevention of tuberculosis (TB). It works by blocking the formation of mycobacterial cell wall components, helping stop the growth and spread of TB bacteria. This strength is widely used in government healthcare programs, DOTS therapy, and clinical TB management.
Isoniazid 300 mg is recommended in active TB infection and is often combined with other antitubercular drugs depending on treatment stage and severity. It may also be prescribed for latent TB infection in high-risk individuals to prevent activation of disease.
Due to the continued medical demand for tuberculosis management, Isoniazid is a high-priority essential medicine and a consistent-moving product across hospitals, clinics, public health programs, and pharma distribution channels.
Isohype 300 Tablet belongs to the Pulmonology and Anti-Infective segment, making it suitable for PCD franchise expansion, institutional supply, tender business, and third-party manufacturing opportunities.